Plasma phosphor-tau217 in Alzheimer’s disease and other neurodegenerative disorders

Takeaway

  • Plasma tau phosphorylated at threonine (P-tau217) discriminated Alzheimer’s disease (AD) from other neurodegenerative diseases with higher accuracy than established plasma- and magnetic resonance imaging (MRI)-based biomarkers but did not differ from key cerebrospinal fluid (CSF)- or positron emission tomography (PET)-based markers.

Why this matters

  • The increasing global prevalence of dementia, especially that linked to AD, has greatly increased the need for early, accurate diagnostic markers for optimal disease management.

  • Identification of early diagnostic markers for AD may help to expedite appropriate treatment for these individuals, leading to improved patient outcomes.